AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,733.50GBp
23 Jan 2015
Change (% chg)

44.00p (+0.94%)
Prev Close
4,689.50p
Open
4,692.50p
Day's High
4,741.00p
Day's Low
4,682.00p
Volume
2,355,710
Avg. Vol
2,362,896
52-wk High
4,946.41p
52-wk Low
3,663.70p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments... (more)

Overall

Beta: 0.40
Market Cap(Mil.): £59,790.89
Shares Outstanding(Mil.): 1,263.14
Dividend: 53.10
Yield (%): 3.59

Financials

  AZN.L Industry Sector
P/E (TTM): 87.43 40.21 40.82
EPS (TTM): 0.54 -- --
ROI: 2.60 19.07 18.35
ROE: 4.71 19.85 19.25
Search Stocks

AstraZeneca heart drug boosted by major clinical trial success

LONDON - AstraZeneca's blood-thinning drug Brilinta cut the risk of death or heart attack in patients with a history of previous attacks, according to a major clinical trial that will boost hopes for the closely watched product.

14 Jan 2015

UPDATE 2-AstraZeneca heart drug boosted by major clinical trial success

* AstraZeneca shares up 1.5 percent (Adds executive interview, consensus sales forecast, more reaction)

14 Jan 2015

Europe shares fall as growth fears hit energy, miners

LONDON, Jan 14 - European shares fell at the open on Wednesday, mirroring a slump in copper and oil prices after the World Bank cut its global growth forecast for this year.

14 Jan 2015

AstraZeneca loses German court appeal over Seroquel XR drug patent

- Britain's AstraZeneca Plc on Tuesday lost an appeal in Germany's Federal Court against generic drugmakers selling cheap copies of its anti-psychotic drug Seroquel XR.

13 Jan 2015

AstraZeneca loses German court appeal over Seroquel XR drug patent

KARLSRUHE, Germany - Britain's AstraZeneca Plc on Tuesday lost an appeal in Germany's Federal Court against generic drugmakers selling cheap copies of its anti-psychotic drug Seroquel XR.

13 Jan 2015

AstraZeneca loses German court appeal over Seroquel XR drug patent

KARLSRUHE, Germany, Jan 13 - Britain's AstraZeneca Plc on Tuesday lost an appeal in Germany's Federal Court against generic drugmakers selling cheap copies of its anti-psychotic drug Seroquel XR.

13 Jan 2015

Merck, Bristol heat up immunotherapy race in lung cancer

- Bristol-Myers Squibb and Merck & Co broke further away from rival drugmakers in the race to treat lung cancer with a new generation of immune system therapies, adding pressure on the likes of Roche and AstraZeneca to play catch-up.

12 Jan 2015

Merck, Bristol heat up immunotherapy race in lung cancer

Jan 12 - Bristol-Myers Squibb and Merck & Co broke further away from rival drugmakers in the race to treat lung cancer with a new generation of immune system therapies, adding pressure on the likes of Roche and AstraZeneca to play catch-up.

12 Jan 2015

AstraZeneca in cancer viruses deal with Omnis Pharmaceuticals

LONDON - AstraZeneca said on Monday its MedImmune biotech unit had struck a deal with unlisted U.S. company Omnis Pharmaceuticals on the development of cancer-fighting oncolytic viruses.

12 Jan 2015

AstraZeneca in cancer viruses deal with Omnis Pharmaceuticals

LONDON, Jan 12 - AstraZeneca said on Monday its MedImmune biotech unit had struck a deal with unlisted U.S. company Omnis Pharmaceuticals on the development of cancer-fighting oncolytic viruses.

12 Jan 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Wright Reports
$75.00
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks